Icosavax Stock Price, News & Analysis (NASDAQ:ICVX) $9.94 -0.29 (-2.83%) (As of 02:34 PM ET) Add Compare Share Share Today's Range$9.92▼$10.8250-Day Range$5.95▼$11.2452-Week Range$3.09▼$16.45Volume575,292 shsAverage Volume230,907 shsMarket Capitalization$497.89 millionP/E RatioN/ADividend YieldN/APrice Target$26.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Icosavax MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside166.6% Upside$26.50 Price TargetShort InterestBearish5.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.81Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.20) to ($2.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector656th out of 949 stocksBiological Products, Except Diagnostic Industry109th out of 163 stocks 3.5 Analyst's Opinion Consensus RatingIcosavax has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.50, Icosavax has a forecasted upside of 166.6% from its current price of $9.94.Amount of Analyst CoverageIcosavax has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.49% of the float of Icosavax has been sold short.Short Interest Ratio / Days to CoverIcosavax has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Icosavax has recently increased by 2.89%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIcosavax does not currently pay a dividend.Dividend GrowthIcosavax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ICVX. Previous Next 2.7 News and Social Media Coverage News SentimentIcosavax has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Icosavax this week, compared to 1 article on an average week.Search Interest7 people have searched for ICVX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Icosavax insiders have not sold or bought any company stock.Percentage Held by Insiders30.59% of the stock of Icosavax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.59% of the stock of Icosavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Icosavax are expected to decrease in the coming year, from ($2.20) to ($2.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Icosavax is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Icosavax is -4.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIcosavax has a P/B Ratio of 2.14. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Icosavax Stock (NASDAQ:ICVX)Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.Read More ICVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ICVX Stock News HeadlinesNovember 27, 2023 | msn.comIcosavax (ICVX) Price Target Increased by 5.00% to 24.99November 26, 2023 | americanbankingnews.comIcosavax (NASDAQ:ICVX) Trading 6.1% Higher November 30, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 18, 2023 | msn.comGuggenheim Initiates Coverage of Icosavax (ICVX) with Buy RecommendationNovember 17, 2023 | realmoney.thestreet.comIcosavax initiated with a Buy at GuggenheimNovember 16, 2023 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on Icosavax (ICVX)November 15, 2023 | markets.businessinsider.comTarget Reports Earnings Beat, Joins AST SpaceMobile, Dada Nexus And Other Big Stocks Moving Higher On WednesdayNovember 15, 2023 | finanznachrichten.deIcosavax, Inc.: Icosavax Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 30, 2023 | Edge On The Street (Ad)Gold Could Be Heading for Record Highs - But How to Play It?According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold. November 14, 2023 | finance.yahoo.comIcosavax Inc (ICVX) Reports Q3 2023 Financial Results and Corporate ProgressNovember 14, 2023 | finance.yahoo.comIcosavax Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 10, 2023 | seekingalpha.comAura Biosciences GAAP EPS of -$0.48November 8, 2023 | finance.yahoo.comIcosavax to Participate in the Jefferies London Healthcare ConferenceOctober 31, 2023 | finance.yahoo.comIcosavax to Participate in the Guggenheim Healthcare Talks 5th Annual Inflammation, Neurology & Immunology (INI) ConferenceOctober 30, 2023 | finance.yahoo.comWe're Not Very Worried About Icosavax's (NASDAQ:ICVX) Cash Burn RateSeptember 19, 2023 | finance.yahoo.comIcosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023August 15, 2023 | markets.businessinsider.comJefferies Reaffirms Their Buy Rating on Icosavax (ICVX)August 14, 2023 | finance.yahoo.comIcosavax Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 8, 2023 | finance.yahoo.comIcosavax Reports Positive 12-Month Durability Data for VLP Vaccine Candidate IVX-121 Against RSV and Initial Evidence for Revaccination PotentialJuly 2, 2023 | finance.yahoo.comIcosavax, Inc. (NASDAQ:ICVX) is largely controlled by institutional shareholders who own 53% of the companyJune 20, 2023 | finance.yahoo.comIcosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older AdultsJune 15, 2023 | benzinga.comIcosavax EVP Awarded $1.79M Worth of Stock OptionsMay 24, 2023 | finance.yahoo.comIcosavax (ICVX) Up on Positive VLP Vaccine Candidate DataMay 23, 2023 | finance.yahoo.comWhy Shares of Icosavax Jumped on TuesdayMay 23, 2023 | msn.comCohBar, Ocean Biomedical top healthcare gainers; NantHealth, Microbot among losersMay 23, 2023 | markets.businessinsider.comIcosavax Touts Encouraging Early-Cut Data From Phase 1 Trial Of RSV VaccineMay 22, 2023 | benzinga.comIcosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older AdultsSee More Headlines Receive ICVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Icosavax and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)4/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ICVX CUSIPN/A CIK1786255 Webicosavax.com Phone206-737-0085FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$26.50 High Stock Price Target$28.00 Low Stock Price Target$25.00 Potential Upside/Downside+159.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-91,760,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.06% Return on Assets-39.53% Debt Debt-to-Equity RatioN/A Current Ratio18.06 Quick Ratio18.06 Sales & Book Value Annual Sales$580,000.00 Price / Sales883.48 Cash FlowN/A Price / Cash FlowN/A Book Value$4.64 per share Price / Book2.20Miscellaneous Outstanding Shares50,090,000Free Float34,767,000Market Cap$512.42 million OptionableNot Optionable Beta0.45 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Adam K. Simpson (Age 47)President, CEO, Co-Founder & Director Comp: $855.95kMr. Niranjan Kanesa-thasan M.D. (Age 62)Chief Medical Officer Comp: $641.55kDr. Cassia Cearley Ph.D. (Age 40)Treasurer & Chief Business Officer Comp: $632.15kMr. Neil King Ph.D.Chair of Scientific Advisory Board & Co-FounderDr. David Baker M.D.Ph.D., Co-founder & Member of Scientific Advisory BoardMr. Thomas Joseph Russo C.F.A. (Age 51)Chief Financial Officer Comp: $525.27kMs. Jennifer RaymondSenior Vice President of Technical OperationsMs. Elizabeth Bekiroglu (Age 53)General Counsel & Corporate Secretary Comp: $230.74kMs. Lori StewartSenior Vice President of People & CultureDr. Ami Shah Brown MPHPh.D., Senior Vice President of Regulatory AffairsMore ExecutivesKey CompetitorsCaribou BiosciencesNASDAQ:CRBU4D Molecular TherapeuticsNASDAQ:FDMTTarsus PharmaceuticalsNASDAQ:TARSAnavex Life SciencesNASDAQ:AVXLCabaletta BioNASDAQ:CABAView All CompetitorsInsiders & InstitutionsGSA Capital Partners LLPBought 25,618 shares on 11/15/2023Ownership: 0.051%California State Teachers Retirement SystemSold 3,085 shares on 11/14/2023Ownership: 0.012%FMR LLCSold 1,249,174 shares on 11/13/2023Ownership: 10.897%Northern Trust CorpBought 28,686 shares on 11/13/2023Ownership: 0.543%Federated Hermes Inc.Bought 3,685 shares on 11/13/2023Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions ICVX Stock Analysis - Frequently Asked Questions Should I buy or sell Icosavax stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Icosavax in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICVX shares. View ICVX analyst ratings or view top-rated stocks. What is Icosavax's stock price target for 2024? 3 brokers have issued 12-month price objectives for Icosavax's stock. Their ICVX share price targets range from $25.00 to $28.00. On average, they anticipate the company's share price to reach $26.50 in the next twelve months. This suggests a possible upside of 166.6% from the stock's current price. View analysts price targets for ICVX or view top-rated stocks among Wall Street analysts. How have ICVX shares performed in 2023? Icosavax's stock was trading at $7.94 at the beginning of the year. Since then, ICVX shares have increased by 25.2% and is now trading at $9.94. View the best growth stocks for 2023 here. When is Icosavax's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our ICVX earnings forecast. How were Icosavax's earnings last quarter? Icosavax, Inc. (NASDAQ:ICVX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.81. The company had revenue of $1.83 million for the quarter, compared to analyst estimates of $3.30 million. What ETFs hold Icosavax's stock? ETFs with the largest weight of Icosavax (NASDAQ:ICVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) and Fidelity Disruptive Medicine ETF (FMED). When did Icosavax IPO? (ICVX) raised $150 million in an IPO on Thursday, July 29th 2021. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. Who are Icosavax's major shareholders? Icosavax's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (10.90%), Citigroup Inc. (0.63%), Northern Trust Corp (0.54%), Barclays PLC (0.40%), Bank of New York Mellon Corp (0.18%) and GSA Capital Partners LLP (0.05%). Insiders that own company stock include Adam K Simpson, Cassia Cearley, Charles E Richardson, Douglas Holtzman, Elizabeth Bekiroglu, Mark Mcdade, Niranjan Kanesa-Thasan, Ra Capital Management, LP and Thomas Joseph Russo. View institutional ownership trends. How do I buy shares of Icosavax? Shares of ICVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ICVX) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Icosavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.